DIPROLENE (betamethasone dipropionate) by Merck & Co. is signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action of diprolene ointment in corticosteroid responsive dermatoses is unknown. First approved in 1983.
Drug data last refreshed 5h ago · AI intelligence enriched 6d ago
DIPROLENE (betamethasone dipropionate) is an augmented topical corticosteroid ointment approved in 1983 for treating corticosteroid-responsive dermatoses. The precise mechanism remains unknown, but it modulates signaling, immune function, inflammation, and protein regulation at the skin level. It is applied topically for inflammatory and allergic skin conditions.
Limited spending and small claim volume suggest a mature, low-priority product with minimal team expansion opportunities at the sponsor level.
signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action of DIPROLENE Ointment in corticosteroid responsive dermatoses is unknown.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
The Effect of Intra-sinus Application of Betamethasone Dipropionate Nasal Cream on Patients with Chronic Rhinosinusitis Post Functional Endoscopic Sinus Surgery (FESS)
A Study to Assess Treatment Satisfaction, Patient-reported Outcomes, Effectiveness, and Safety of a Fixed-dose Combination of Calcipotriene/Betamethasone Dipropionate PAD Cream in the Treatment of Mild-to-moderate Plaque Psoriasis of the Scalp in Adults
Treatment of Eosinophilic Chronic Rhinosinusitis Utilizing Betamethasone Dipropionate Nasal Cream
Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamics Effect of Calcipotriol/Betamethasone Dipropionate in a New Administration Form in Subjects With Chronic Plaque Psoriasis.
Skin Irritation of LEO 90100 Foam (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Healthy Japanese Subjects
Worked on DIPROLENE at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moDIPROLENE offers minimal career growth opportunities given zero linked job openings, approaching LOE status, and low commercial prioritization at sponsor level. Roles available would focus on defensive market management, generic competition mitigation, and operational efficiency rather than innovation or expansion.